Biocept (NASDAQ: RDNT) and RadNet (NASDAQ:RDNT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility & Risk

Biocept has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, RadNet has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Insider and Institutional Ownership

56.9% of RadNet shares are held by institutional investors. 2.6% of Biocept shares are held by company insiders. Comparatively, 7.6% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biocept and RadNet, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biocept 0 1 1 0 2.50
RadNet 0 0 1 2 3.67

Biocept currently has a consensus price target of $1.25, indicating a potential downside of 59.15%. RadNet has a consensus price target of $14.67, indicating a potential upside of 7.84%. Given RadNet’s stronger consensus rating and higher possible upside, analysts clearly believe RadNet is more favorable than Biocept.

Valuation and Earnings

This table compares Biocept and RadNet’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biocept $5.07 million 1.37 -$21.61 million ($23.72) -0.13
RadNet $922.19 million 0.71 $50,000.00 $0.29 46.90

RadNet has higher revenue and earnings than Biocept. Biocept is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.


This table compares Biocept and RadNet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biocept -561.47% -445.14% -196.63%
RadNet -0.64% 17.00% 1.84%


RadNet beats Biocept on 12 of the 14 factors compared between the two stocks.

Biocept Company Profile

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

RadNet Company Profile

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.